Fosaprepitant

證據等級: L5

預測適應症: 10 個

Fosaprepitant: From Chemotherapy-Induced Nausea and Vomiting to Nephrogenic Syndrome of Inappropriate Antidiuresis

One-Sentence Summary

Fosaprepitant is an NK1 (neurokinin-1/substance P) receptor antagonist, the intravenous prodrug of aprepitant, whose established supportive-care role in chemotherapy-induced nausea and vomiting is reflected in the clinical trial evidence within this pack. The TxGNN model predicts it may be effective for Nephrogenic Syndrome of Inappropriate Antidiuresis, but currently 0 clinical trials and 0 publications support this specific indication — the prediction rests solely on the network model.

Quick Overview

Item	Content
Original Indication	Not specified in Norway regulatory data; trial evidence elsewhere in this pack indicates established use in chemotherapy-induced nausea/vomiting prophylaxis
Predicted New Indication	Nephrogenic syndrome of inappropriate antidiuresis
TxGNN Prediction Score	99.92%
Evidence Level	L5
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (marked as a data gap in this evidence pack). Based on the information present, Fosaprepitant belongs to the NK1 receptor antagonist class, and trial evidence elsewhere in this pack (e.g. studies of fosaprepitant/aprepitant combined with 5-HT3 antagonists and dexamethasone in cisplatin-based chemotherapy) indicates its established role as an antiemetic in oncology supportive care.

Nephrogenic syndrome of inappropriate antidiuresis (NSIAD), however, is a distinct disorder driven by gain-of-function mutations in the vasopressin V2 receptor, causing water retention independent of circulating vasopressin. No mechanistic link between substance P/NK1 signaling and V2-receptor-mediated free water reabsorption is documented in this evidence pack. This prediction should therefore be treated as a network-derived hypothesis rather than a mechanistically grounded candidate; independent pharmacological or physiological rationale would need to be established before further investment.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Norway Market Information

Fosaprepitant is currently not marketed in Norway (0 authorizations on record), so no license/product information is available in this evidence pack.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication (NSIAD) has no supporting clinical trials or literature and no established mechanistic rationale connecting NK1 antagonism to vasopressin V2-receptor pathophysiology — evidence level L5, model prediction only. The drug is also not currently marketed in Norway, adding regulatory uncertainty on top of the evidentiary gap.

To proceed, the following is needed:

Confirmed mechanism of action (MOA) data (currently a flagged, blocking data gap)
TFDA/regulatory label warnings and contraindications (currently a flagged, blocking data gap)
Preclinical or mechanistic evidence linking substance P/NK1 signaling to AVP/V2-receptor-mediated water retention
Any case reports, observational data, or trials specifically involving NSIAD or related SIADH-spectrum disorders
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.